Literature DB >> 24170026

What does MRD in leukemia really mean?

J M Goldman1, R P Gale1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24170026     DOI： 10.1038/leu.2013.318

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Who is the best alternative allotransplant donor?

Authors:  R P Gale; M Eapen
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 2.  Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.

Authors:  Peter Hokland; Hans B Ommen; Matthew P Mulé; Christopher S Hourigan
Journal:  Semin Hematol       Date:  2015-04-07       Impact factor: 3.851

Review 3.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

Review 4.  Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.

Authors:  Anne Stidsholt Roug; Hans Beier Ommen
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

5.  Next generation MRD.

Authors:  Christopher S Hourigan
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

6.  Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Authors:  Matthew P Mulé; Gabriel N Mannis; Brent L Wood; Jerald P Radich; Jimmy Hwang; Nestor R Ramos; Charalambos Andreadis; Lloyd Damon; Aaron C Logan; Thomas G Martin; Christopher S Hourigan
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-17       Impact factor: 5.742

Review 7.  Should persons with acute myeloid leukemia have a transplant in first remission?

Authors:  R P Gale; P H Wiernik; H M Lazarus
Journal:  Leukemia       Date:  2014-04-14       Impact factor: 11.528

Review 8.  Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.

Authors:  Kristen Pettit; Wendy Stock; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2016-07

Review 9.  Evaluating measurable residual disease in acute myeloid leukemia.

Authors:  Farhad Ravandi; Roland B Walter; Sylvie D Freeman
Journal:  Blood Adv       Date:  2018-06-12

10.  A multigene array for measurable residual disease detection in AML patients undergoing SCT.

Authors:  M Goswami; K S McGowan; K Lu; N Jain; J Candia; N F Hensel; J Tang; K R Calvo; M Battiwalla; A J Barrett; C S Hourigan
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.